12:00 AM
 | 
May 28, 2012
 |  BC Week In Review  |  Company News  |  Other News

iPierian neurology, gene/cell therapy news

iPierian Inc., South San Francisco, Calif.
Business: Neurology, Gene/Cell therapy
iPierian announced it selected the first two development programs for its pipeline: mAbs targeting microtubule-associated protein tau (MAPT; tau;

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >